Cargando…
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
Current antibody-drug conjugates (ADCs) target internalising receptors on cancer cells leading to intracellular drug release. Typically, only a subset of patients with solid tumours has sufficient expression of such a receptor, while there are suitable non-internalising receptors and stroma targets....
Autores principales: | Rossin, Raffaella, Versteegen, Ron M., Wu, Jeremy, Khasanov, Alisher, Wessels, Hans J., Steenbergen, Erik J., ten Hoeve, Wolter, Janssen, Henk M., van Onzen, Arthur H. A. M., Hudson, Peter J., Robillard, Marc S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935733/ https://www.ncbi.nlm.nih.gov/pubmed/29728559 http://dx.doi.org/10.1038/s41467-018-03880-y |
Ejemplares similares
-
Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
por: Rossin, Raffaella, et al.
Publicado: (2019) -
Antitumour Drug-Radiation Interactions
por: Carmichael, J.
Publicado: (1992) -
Tin-based Antitumour Drugs
por: Gielen, Marcel
Publicado: (1994) -
MDR1 causes resistance to the antitumour drug miltefosine
por: Rybczynska, M, et al.
Publicado: (2001) -
Tetrazine—trans-Cyclooctene
Chemistry Applied to Fabricate Self-Assembled Fluorescent and Radioactive
Nanoparticles for in Vivo Dual Mode Imaging
por: van Onzen, Arthur H. A. M., et al.
Publicado: (2019)